Bioavalaibility and pharmacokinetic comparison of two formulations of metformin 850 mg tablets in healthy Colombian volunteers

https://doi.org/10.25100/cm.v42i1.754

Article Sidebar

PDF HTML

Published: Jul 29, 2024
Updated: 2024-07-29
Versions:
2024-07-29 (2)
Issue: Vol. 42 No. 1 (2011)
Section Original Articles

Publcation metrics

828 | 828 | 263




 


Main Article Content

Authors

Gloria Holguín
Fanny Cuesta
Rosendo Archbold
Margarita Restrepo
Sergio Parra
Lina Peña
Blanca Montoya
Juan Carlos Ríos
Victoria Eugenia Toro
Adriana Ruiz
Abstract
urpose: The aim of this study was to compare the bioavailability of two formulations of metformin 850 mg tablets: Glucophage® from Merck Santè laboratories (reference product) and Metformin from Winthrop Pharmaceuticals de Colombia SA (test product) in healthy Colombian volunteers.
Methods: A random, double blind, two-period, two-week wash out period, crossover study was performed in 24 healthy male and female volunteers for a single 850-mg dose of metformin tablets administrated with 240 ml of water after 12 hours of fasting. Once the drug was administrated, blood samples were collected before and within 24 hour, and plasma metformin concentration was determined by using a validated HPLC method. Pharmacokinetic parameters such as Cmax, AUC0-96h, AUC0-∞, and Tmax were determined. The formulations were considered bioequivalent if the logarithmic mean ratios of ln-transformed Cmax and AUC0-∞ values were within the equivalence range of 80%-125%.
Results: ANOVA analysis of the ln-transformed Cmax and AUC0-∞ indicated that none of the effects examined (formulation, period, within and between-subjet variances and carry over) was statistically significant. The mean (±SD) of Cmax 1217.38 (± 251.72) ng/ml vs. 1305.25 (± 301.06) ng/ml, AUC0-96h 1363.49 (± 315.51) ng.h/ml vs. 1584.82 (± 368.75) ng.h/ml, AUC0-∞, 7155.75 (± 1440.74) ng.h/ml vs. 7777.08 (± 1896.49) ng.h/ml, and Tmax 2.57 (± 0.93) h vs. 2.22 (± 0.94) h were obtained with test and reference formulations, respectively. These pharmacokinetic parameters presented differences with the results from other published papers. The 90% confidence interval of the logarithmic ratio of AUC0-∞ and Cmax was within the range of 80-125%.
Conclusions: In this study in healthy Colombian volunteers, a single 850-mg dose of metformin tablet test formulation met the criteria for bioequivalence to the reference formulation based on pharmacokinetic parameters AUC0-∞ and Cmax.
Keywords
  • Metformin
  • Bioequivalence
  • Bioavailability
  • Pharmacokinetics
  • Interchange of drugs
  • Area under curve
References

Dunn CJ, Peters DJ. Metformin. A review of its pharma-cological properties and therapeutic use in non–insulin-dependent diabetes mellitus. Drugs. 1995; 49: 721-49.2.Scheen AJ. Clinical pharmacokinetics of metformin. ClinPharmacokinet. 1996; 30: 359-71.3.Pentikainen PJ. Bioavailability of metformin. Comparison ofsolution, rapidly dissolving tablet and three sustained releaseproducts. Int J Clin Pharmacol Ther Toxicol. 1986; 24: 213-20.4.Hale TW, Kristensen LP, Hackett LP, Kohan R, Ilett KF.Transfer of metformin into human milk. Diabaetologia. 2002;1509-14.5.Najib N, Idkaidek N, Beshtawi M, Bader M, Admour I, AlamSM,et al. Bioequivalence evaluation of two brands ofmetformin 500 mg tablets (dialon1 & glucophage1) in healthyhuman volunteers. Biopharm Drug Dispos. 2002; 23: 301-6.6.Zapater P, Horga JF. Bioequivalencia y genéricos. Los estu-

Colombia Médica Vol. 42 Nº 1, 2011 (Enero-Marzo)dios de bioequivalencia. I Una aproximación a sus basesteóricas, diseño y realización. Rev Neurol. 1999; 29: 1235-46.7.Julious S. Tutorial in biostatistics. Sample sizes for clinicaltrials with normal data. Stat Med. 2004; 23: 1921-86.8.Yuen KH, Peh KK. Simple high-performance liquidchromatographic method for the determination of metforminin human plasma. J Chromatogr B Biomed Appl. 1998; 710:243-46.9.Food and Drug Administration (FDA). 2001. Guidance forIndustry. Bioanalytical Method Validation. [Accessed 25Nov 2009]. Available: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf10. Food and Drug Administration (FDA). 2001. Guidance forIndustry - Statistical Approaches to Establishing Bio-equivalence. [Accessed 25 Nov 2009]. Available: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070244.pdf11. Food and Drug Administration (FDA) 2003. Guidance forindustry, bioavailability and bioequivalence. Studies for orallyadministered drug products-general considerations. [Accessed24 Nov 2009] Available: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070124.pdf12. Sambol NC, Chiang J, O’Conner M, Liu CY, Lin ET, GoodmanAM, et al. Pharmacokinetics and pharmacodynamics ofmetformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus. J Clin Pharmacol. 1996; 36:1012-21.13. Scheen AJ. Clinical pharmacokinetics of metformin. ClinPharmacokinet. 1996; 30: 359-71.14. Atanasova I, Bozhinova K, Todorova D, Terziivanov D.Pharmacokinetics and comparative bioavailability of twometformin formulations after single-dose administration inhealthy subjects. Clin Drug Invest. 2003; 23: 743-9.15. Vlahov V, Thyroff-Friesinger U, Koytchev R, Bakracheva N,Gatchev E. Bioequivalence studies with metformin:comparability of reference tablets from different origins. Int JClin Pharmac Ther. 2005; 43: 457-62.16. Cuesta F, Holguín G, Archbold R, Restrepo M, Peña L,Montoya B. et al. Bioequivalencia de dos formulaciones demetformina, tabletas con 850 mg, en voluntarios sanos colom-bianos. IATREIA. 2005; 18: 289-301.17. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996; 334:574-9., Hopley CW, Aquilante CL. Inter-individualvariability in oral antidiabetic drug disposition and response:the role of drug transporter polymorphisms. Expert Opin DrugMetabolism Toxicol. 2008; 4: 529-44.19. Marathe P, Wen Y, Norton J, et al. Effect of altered gastricemptying and gastrointestinal motility on metforminabsorption. Br J Clin Pharmacol. 2000; 50: 325-32.20. Cheng CL, Yu LX, Lee HL, Yang CY, Lue CS, Chou CH.Biowaiver extension to BCS class III high solubility-lowpermeability drugs: bridging evidence for metforminimmediate-release tablet. Eur J Pharm Sci. 2004; 22: 297-304.21. Yuen KH, Wong JW, Billa N, Julianto T, Toh WT.Bioequivalence of a generic metformin tablet preparation. IntJ Clin Pharmac Ther. 1999; 37: 319-22

How to Cite
Holguín, G., Cuesta, F., Archbold, R., Restrepo, M., Parra, S., Peña, L., Montoya, B., Ríos, J. C., Toro, V. E., & Ruiz, A. (2024). Bioavalaibility and pharmacokinetic comparison of two formulations of metformin 850 mg tablets in healthy Colombian volunteers. Colombia Medica, 42(1), 81–87. https://doi.org/10.25100/cm.v42i1.754 (Original work published March 12, 2011)
Usage statistics

Downloads

Download data is not yet available.
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

The copy rights of the articles published in Colombia Médica belong to the Universidad del Valle. The contents of the articles that appear in the Journal are exclusively the responsibility of the authors and do not necessarily reflect the opinions of the Editorial Committee of the Journal. It is allowed to reproduce the material published in Colombia Médica without prior authorization for non-commercial use